Development and evaluation of a novel method for preclinical measurement of tissue vascular volume.
Identification of clinically predictive models of disposition kinetics for antibody therapeutics is an ongoing pursuit in drug development. To encourage translation of drug candidates from early research to clinical trials, clinical diagnostic agents may be used to characterize antibody disposition in physiologically relevant preclinical models. TechneScan PYP was employed to measure tissue vascular volumes (V(v)) in healthy mice. Two methods of red blood cell (RBC) labeling were compared: a direct in vivo method that is analogous to a clinical blood pool imaging protocol, and an indirect method in which radiolabeled blood was transfused from donor mice into recipient mice. The indirect method gave higher precision in RBC labeling yields, lower V(v) values in most tissues, and lower (99m)Tc uptake in kidneys and bladder by single photon emission computed tomographic (SPECT) imaging relative to the direct method. Furthermore, the relative influence of each method on the calculated area under the first 7 days of the concentration-time curve (AUC(0-7)) of an IgG in nude mice was assessed using a physiologically based pharmacokinetic model. The model was sensitive to the source of V(v) values, whether obtained from the literature or measured by either method, when used to predict experimental AUC(0-7) values for radiolabeled trastuzumab in healthy murine tissues. In summary, a novel indirect method for preclinical determination of V(v) offered higher precision in RBC labeling efficiency and lower renal uptake of (99m)Tc than the direct method. In addition, these observations emphasize the importance of obtaining accurate physiological parameter values for modeling antibody uptake.
Boswell
C Andrew
CA
Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Research and Early Development, South San Francisco, CA 94080, USA.
Ferl
Gregory Z
GZ
Mundo
Eduardo E
EE
Schweiger
Michelle G
MG
Marik
Jan
J
Reich
Michael P
MP
Theil
Frank-Peter
FP
Fielder
Paul J
PJ
Khawli
Leslie A
LA
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics; D001808:Blood Vessels / Q000033:anatomy & histology; D001810:Blood Volume; D002626:Chemistry, Pharmaceutical; D055808:Drug Discovery; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D064847:Multimodal Imaging; D010599:Pharmacokinetics; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D016698:Technetium Tc 99m Pyrophosphate; D014018:Tissue Distribution; D014057:Tomography, X-Ray Computed; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D019275:Radiopharmaceuticals; D016698:Technetium Tc 99m Pyrophosphate; D000068878:Trastuzumab